Bisphosphonates: The First-Line Defense Against Osteoporosis
Bisphosphonates are the most widely prescribed osteoporosis drugs, binding to bone mineral and triggering osteoclast death to slow bone resorption.
Bisphosphonates are the most widely prescribed drug class for Osteoporosis: When Bone Breakdown Outpaces Bone Building. They work by binding tightly to bone mineral (hydroxyapatite) and being selectively taken up by Osteoclasts: The Bone-Resorbing Cells That Drive Osteoporosis When Overactive during bone resorption, triggering apoptosis (cell death) and reducing bone breakdown. ## Common Agents - **Alendronate** (Fosamax): Weekly oral tablet, most prescribed - **Risedronate** (Actonel): Weekly oral tablet - **Zoledronic acid** (Reclast): Annual IV infusion — highest potency, best adherence - **Ibandronate** (Boniva): Monthly oral or quarterly IV ## Clinical Effect Bisphosphonates reduce vertebral fracture risk by ~50% and hip fracture risk by ~40% over 3 years. They accumulate in bone and persist for years after discontinuation — a "drug holiday" is often recommended after 5 years of oral or 3 years of IV therapy. ## Risks - **Osteonecrosis of the jaw**: Rare (~1 in 10,000–100,000 for oral doses), more common with high-dose IV therapy for cancer - **Atypical femoral fractures**: Very rare stress fractures in the femur shaft associated with long-term use (>5 years) - GI irritation with oral forms (must take on empty stomach, remain upright 30 minutes)